Relypsa, Inc. Completes Patient Enrollment in Pivotal Phase 3 Program for the Treatment of Hyperkalemia
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Relypsa, Inc., a clinical-stage biopharmaceutical company, today announced that the company has completed enrollment of its pivotal phase 3 program of patiromer for the treatment of hyperkalemia in patients with chronic kidney disease (CKD). The two part phase 3 clinical trial is being conducted under an agreed upon special protocol assessment (SPA) with the U.S. Food and Drug Administration as follows:
Help employers find you! Check out all the jobs and post your resume.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Relypsa, Inc., a clinical-stage biopharmaceutical company, today announced that the company has completed enrollment of its pivotal phase 3 program of patiromer for the treatment of hyperkalemia in patients with chronic kidney disease (CKD). The two part phase 3 clinical trial is being conducted under an agreed upon special protocol assessment (SPA) with the U.S. Food and Drug Administration as follows:
Help employers find you! Check out all the jobs and post your resume.